4D Molecular Therapeutics, Inc.FDMT
Price (close)
$14.71
Market cap
$812.2M
P/E
—
Revenue (TTM)
$92.0M
Net income
-$179.2M
Dividend yield
—
1-year total return
74.7%
Net margin
-194.7%
Revenue growth
278712.0%
Debt / equity
0.05x
What 4D Molecular Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37,000 | $85.2M |
| Net income | -$56.7M | -$71.3M | -$107.5M | -$100.8M | -$160.9M | -$140.1M |
| Free cash flow | -$51.9M | -$78.2M | -$98.2M | -$78.6M | -$138.4M | -$109.6M |
More on FDMT.
- 4D Molecular Therapeutics, Inc. summary
- 4D Molecular Therapeutics, Inc. financial statements
- 4D Molecular Therapeutics, Inc. key metrics
- 4D Molecular Therapeutics, Inc. health scores and style box
- 4D Molecular Therapeutics, Inc. earnings
- 4D Molecular Therapeutics, Inc. dividends
- 4D Molecular Therapeutics, Inc. valuation
- 4D Molecular Therapeutics, Inc. ownership and insiders
- 4D Molecular Therapeutics, Inc. peers
Figures from 4D Molecular Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.